Analysts Set Immunome, Inc. (NASDAQ:IMNM) Price Target at $33.17

Shares of Immunome, Inc. (NASDAQ:IMNM) have been given a consensus recommendation of “Moderate Buy” by the fourteen research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and thirteen have issued a buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $33.1667.

Several analysts recently issued reports on IMNM shares. Barclays initiated coverage on shares of Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price target on the stock. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research note on Friday, July 17th. Wedbush reaffirmed an “outperform” rating and set a $31.00 price target on shares of Immunome in a research report on Tuesday, July 21st. Finally, Leerink Partners decreased their price target on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research note on Friday, May 15th.

Immunome Stock Performance

Shares of IMNM stock opened at $23.08 on Friday. Immunome has a one year low of $8.66 and a one year high of $27.65. The company has a 50 day moving average price of $21.18 and a 200 day moving average price of $22.03. The firm has a market capitalization of $2.61 billion, a price-to-earnings ratio of -9.70 and a beta of 2.07.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.12. As a group, equities analysts forecast that Immunome will post -2.06 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Jean Jacques Bienaime purchased 10,500 shares of Immunome stock in a transaction dated Friday, June 5th. The stock was bought at an average cost of $19.45 per share, with a total value of $204,225.00. Following the purchase, the director owned 43,415 shares in the company, valued at approximately $844,421.75. The trade was a 31.90% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Robert Lechleider sold 55,000 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $19.85, for a total value of $1,091,750.00. Following the completion of the sale, the insider owned 15,805 shares of the company’s stock, valued at $313,729.25. This trade represents a 77.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 472,142 shares of company stock worth $10,262,648. Company insiders own 7.21% of the company’s stock.

Institutional Trading of Immunome

A number of large investors have recently added to or reduced their stakes in the business. Creative Planning grew its holdings in shares of Immunome by 4.0% during the third quarter. Creative Planning now owns 18,664 shares of the company’s stock valued at $219,000 after buying an additional 710 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in Immunome by 14.4% in the 4th quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock worth $159,000 after acquiring an additional 935 shares in the last quarter. California State Teachers Retirement System boosted its position in Immunome by 1.8% during the 4th quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock worth $1,439,000 after acquiring an additional 1,167 shares during the period. Assetmark Inc. boosted its position in Immunome by 46.6% during the 1st quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after acquiring an additional 1,442 shares during the period. Finally, Virtus Investment Advisers LLC grew its stake in Immunome by 16.9% during the 4th quarter. Virtus Investment Advisers LLC now owns 13,593 shares of the company’s stock valued at $292,000 after acquiring an additional 1,970 shares in the last quarter. 44.58% of the stock is currently owned by institutional investors.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.